Physician profile
Benjamin Bird
NPI 1376102962
$930.50
in general payments reported to CMS, 2019-2025
17 companies · $544 in 2025
The $544 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $386 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $117.96 | 2023-2025 | Zeposia |
| Ucb, INC. | $114.74 | 2025 | Zilbrysq, Nayzilam |
| Alexion Pharmaceuticals, INC. | $102.06 | 2023 | Ultomiris |
| Genzyme Corporation | $100.80 | 2023 | |
| Amylyx Pharmaceuticals, INC. | $83.16 | 2023 | Relyvrio |
| Novartis Pharmaceuticals Corporation | $73.19 | 2025 | |
| Amgen INC. | $63.41 | 2025 | Uplizna |
| Axsome Therapeutics, INC. | $50.77 | 2025 | Symbravo |
| Lundbeck LLC | $47.54 | 2025 | Vyepti |
| Argenx US, INC. | $41.47 | 2025 | Vyvgart Hytrulo |
| Emd Serono, INC. | $29.51 | 2025 | |
| Sk Life Science, INC. | $20.48 | 2025 | |
| Acadia Pharmaceuticals INC | $18.65 | 2025 | Nuplazid |
| Abbvie INC. | $18.32 | 2025 | |
| Eisai INC. | $17.94 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $16.40 | 2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $14.10 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Bird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.